Drug Name:
MIRAPEX Rx

Generic Name and Formulations:
Pramipexole dihydrochloride 0.125mg, 0.25mg+, 0.5mg+, 0.75mg, 1mg+, 1.5mg+; tabs; +scored.
Company:
Boehringer Ingelheim Pharmaceuticals
Therapeutic Use:
Indications for MIRAPEX:
Idiopathic Parkinson's disease.
Adult:
May take with food. Gradually increase from initial dose at intervals of 5–7 days. Initially 0.125mg three times daily; max 1.5mg three times daily. Renal impairment: CrCl 30–50mL/min: initially 0.125mg twice daily; max 0.75mg three times daily. CrCl 15–<30mL/min: initially 0.125mg once daily; max 1.5mg once daily. CrCl <15mL/min, hemodialysis: not recommended.
Children:
Not established.
Warnings/Precautions:
See full labeling. Consider discontinuing if excessive daytime sleepiness or if sudden onset of sleep during daily activities occurs. Monitor for drowsiness or sleepiness, orthostatic hypotension, or compulsive behaviors. Renal disease. Sleep disorders. Dyskinesia. Postural deformity; consider dose reduction or discontinuation if occurs. Avoid abrupt cessation (withdraw over 1 week). Elderly may have higher risk of hallucinations. Pregnancy. Nursing mothers: not recommended.
See Also:
Pharmacological Class:
Dopamine agonist (non-ergot).
Interactions:
Consider reducing concomitant levodopa dose. Pramipexole levels increased by cimetidine, possibly other renally-excreted basic drugs (eg, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine). Caution with alcohol, other CNS depressants. May be antagonized by dopamine antagonists (eg, neuroleptics, metoclopramide).
Adverse Reactions:
Early disease: somnolence (including sudden sleep onset), nausea, constipation, dizziness, fatigue, hallucinations, dry mouth, muscle spasms, peripheral edema, insomnia, asthenia, accidental injury, dyspepsia, others. Late disease: dyskinesia, nausea, constipation, hallucinations, headache, anorexia, postural hypotension, extrapyramidal syndrome, insomnia, dizziness, accidental injury, dream abnormalities, confusion, asthenia, somnolence (including sudden sleep onset), dystonia, abnormal gait, hypertonia, dry mouth, amnesia, urinary frequency, leg cramps, others; rhabdomyolysis.
Elimination:
Renal.
Generic Availability:
Tabs 0.125mg, 0.25mg, 0.5mg, 1mg, 1.5mg (YES); 0.75mg (NO); ER tabs 0.375mg, 0.75mg, 1.5mg, 3mg, 4.5mg (YES); 2.25mg, 3.75mg (NO)
How Supplied:
Tabs—90; ER tabs 0.375mg, 0.75mg, 1.5mg—7, 30; 2.25mg, 3mg, 3.75mg, 4.5mg—30
Indications for MIRAPEX:
Moderate-to-severe primary restless legs syndrome.
Adult:
Initially 0.125mg once daily 2–3 hrs before bedtime. If needed, may double dose every 4–7 days. Max 0.5mg/day (doses of 0.75mg/day have been used). Renal impairment: CrCl: 20–60min/mL: increase titration interval to every 14 days if needed.
Children:
Not established.
Warnings/Precautions:
See full labeling. Consider discontinuing if excessive daytime sleepiness or if sudden onset of sleep during daily activities occurs. Monitor for drowsiness or sleepiness, orthostatic hypotension, or compulsive behaviors. Renal disease. Sleep disorders. Dyskinesia. Postural deformity; consider dose reduction or discontinuation if occurs. Avoid abrupt cessation (withdraw over 1 week). Symptoms may shift to early morning hours (rebound) or have an earlier onset (afternoon or evening). Elderly may have higher risk of hallucinations. Pregnancy. Nursing mothers: not recommended.
Pharmacological Class:
Dopamine agonist (non-ergot).
Interactions:
Consider reducing concomitant levodopa dose. Pramipexole levels increased by cimetidine, possibly other renally-excreted basic drugs (eg, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine). Caution with alcohol, other CNS depressants. May be antagonized by dopamine antagonists (eg, neuroleptics, metoclopramide).
Adverse Reactions:
GI upset, somnolence, fatigue, headache, pain, dizziness, influenza, nasal congestion, abnormal dreams; rhabdomyolysis.
Elimination:
Renal.
Generic Availability:
Tabs 0.125mg, 0.25mg, 0.5mg, 1mg, 1.5mg (YES); 0.75mg (NO); ER tabs 0.375mg, 0.75mg, 1.5mg, 3mg, 4.5mg (YES); 2.25mg, 3.75mg (NO)
How Supplied:
Tabs—90; ER tabs 0.375mg, 0.75mg, 1.5mg—7, 30; 2.25mg, 3mg, 3.75mg, 4.5mg—30
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Some Obesity-Related Cancers Increasing in Younger Adults
- Less Diversity in PROM Systems Could Improve Assessing Their Practicality for Cancer Patients, Clinicians
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |